

UC Irvine

UC Irvine Previously Published Works

Title

Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451

Permalink

<https://escholarship.org/uc/item/4pn9p5mn>

Journal

Kidney International, 94(5)

ISSN

0085-2538

Authors

Astor, Brad
Appel, Lawrence J
Levin, Adeera
[et al.](#)

Publication Date

2018-11-01

DOI

10.1016/j.kint.2018.08.009

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Published in final edited form as:

Kidney Int. 2018 November ; 94(5): 1025–1026. doi:10.1016/j.kint.2018.08.009.

Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. *Kidney Int.* 2018;93:1442–1451

The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows:

- **African American Study of Kidney Disease and Hypertension (AASK):** Brad Astor, Lawrence J. Appel; **Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT):** Adeera Levin, Mila Tang, Ognjenka Djurdjev; **Cleveland Clinic CKD Registry Study (CCF):** Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr.; **Chronic Renal Impairment in Birmingham (CRIB):** David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; **Chronic Renal Insufficiency Cohort Study (CRIC):** Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; **Chronic Renal Insufficiency Standards Implementation Study (CRISIS):** Philip A. Kalra, James P. Ritchie, Raman Maharajan, Rachel J. Middleton, Donal J. O'Donoghue; **German Chronic Kidney Disease Study (GCKD):** Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; **Geisinger Health System:** Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; **Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2):** Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; **Gonryo Study:** Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; **Hong Kong CKD Studies:** Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; **Ontario Institute for Clinical Evaluative Sciences, Provincial Kidney, Dialysis and Transplantation program (ICES KDT):** Amit X. Garg, Eric McArthur, Danielle M. Nash; **Maccabi Health System:** Varda Shalev, Gabriel Chodick; **Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN):** Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; **Modification of Diet in Renal Disease Study (MDRD):** Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; **Nanjing CKD Network Cohort Study (Nanjing CKD):** Haitao Zhang; **NephroTest Study (NephroTest):** Benedicte Stengel, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann; **National Renal Healthcare Program – Uruguay (NRHP-URU):** Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola,

Verónica Lamadrid, Laura Sola; **New Zealand Diabetes Cohort Study (NZDCS)**: John F. Collins, C. Raina Elley, Timothy Kenealy; **Parcours de Soins des Personnes Agées (PSPA)**: Olivier Moranne, Cecile Couchoud, Cecile Vigneau; **Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD)**: Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; **Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV)**: Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; **Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL)**: Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; **Stockholm CREATinine Measurements Cohort (SCREAM)**: Juan Jesus Carrero, Alessandro Gasparini, Abdul Rashid Qureshi, Carl-Gustaf Elinder; **Second Manifestations of ARterial Disease Study (SMART)**: Frank L.J. Visseren, Yolanda van der Graaf; **Swedish Renal Registry CKD Cohort (SRR CKD)**: Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; **Sunnybrook Cohort**: David M. Naimark, Navdeep Tangri; **West of Scotland CKD Study**: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.

- **CKD Prognosis Consortium Steering Committee**: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.
- **CKD Prognosis Consortium Data Coordinating Center**: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).
- **Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD**: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).